Literature DB >> 24031134

Upregulation of TIM-3 and PD-1 on CD4+ and CD8+ T Cells Associated with Dysfunction of Cell-Mediated Immunity after Colorectal Cancer Operation.

Yosuke Arai1, Hiroaki Saito, Masahide Ikeguchi.   

Abstract

Surgery has been reported to suppress cell-mediated immunity; however, the detailed mechanisms responsible for this remain unclear. We obtained information on expressions of T-cell immunoglobulin domain and mucin domain 3 (TIM-3) and programmed cell death 1 (PD-1) on both CD4+ and CD8+ T cells postoperatively from colorectal cancer patients and evaluated by multicolor flow cytometry. The functions of CD4+ and CD8+ T cells based on TIM-3 and PD-1 expressions were determined by quantitating the concentration of interferon-γ (IFN-γ) by enzyme-linked immunosorbent assay. The study demonstrated a rapid and significant decrease in number of total lymphocytes, CD4+ T cells and CD8+ T cells. These immune cells reached the minimum on day 1 and then increased, but still significantly decreased on days 3 and 7. The frequency of PD-1+CD4+ T cells and TIM-3+CD4+ T cells significantly increased after colorectal surgery. IFN-γ secretion by PD-1+TIM-3+CD4+ T cells was significantly decreased compared to secretion by either PD-1+TIM3-CD4+ T cells or PD-1-TIM-3-CD4+ T cells. Furthermore, IFN-γ secretion by PD-1+TIM-3+CD8+ T cells was significantly decreased compared to secretion by either PD-1-TIM-3+CD8+ T cells or PD-1-TIM-3-CD8+ T cells. The expression of PD-1 and TIM-3 was closely related to impaired cell-mediated immunity that was observed after surgery for colorectal cancer. New treatment targeting TIM-3 and PD-1 on CD4+ and CD8+ T cells during the perioperative period may provide a breakthrough in the treatment of colorectal cancer patients.

Entities:  

Keywords:  T-cell immunoglobulin domain and mucin domain 3; colorectal cancer; programmed cell death 1; surgical trauma

Year:  2012        PMID: 24031134      PMCID: PMC3727487     

Source DB:  PubMed          Journal:  Yonago Acta Med        ISSN: 0513-5710            Impact factor:   1.641


  35 in total

1.  B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression.

Authors:  Daria Trabattoni; Marina Saresella; Mara Biasin; Adriano Boasso; Luca Piacentini; Pasquale Ferrante; Haidong Dong; Renato Maserati; Gene M Shearer; Lieping Chen; Mario Clerici
Journal:  Blood       Date:  2002-12-05       Impact factor: 22.113

Review 2.  The PD-1-PD-L pathway in immunological tolerance.

Authors:  Taku Okazaki; Tasuku Honjo
Journal:  Trends Immunol       Date:  2006-02-24       Impact factor: 16.687

3.  Laparoscopic surgery versus open surgery for colon cancer: short-term outcomes of a randomised trial.

Authors:  Ruben Veldkamp; Esther Kuhry; Wim C J Hop; J Jeekel; G Kazemier; H Jaap Bonjer; Eva Haglind; Lars Påhlman; Miguel A Cuesta; Simon Msika; Mario Morino; Antonio M Lacy
Journal:  Lancet Oncol       Date:  2005-07       Impact factor: 41.316

4.  Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease.

Authors:  Laurent Monney; Catherine A Sabatos; Jason L Gaglia; Akemi Ryu; Hanspeter Waldner; Tatyana Chernova; Stephen Manning; Edward A Greenfield; Anthony J Coyle; Raymond A Sobel; Gordon J Freeman; Vijay K Kuchroo
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

5.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

6.  Suppression of cellular immunity by surgical stress.

Authors:  K Ogawa; M Hirai; T Katsube; M Murayama; K Hamaguchi; T Shimakawa; Y Naritake; T Hosokawa; T Kajiwara
Journal:  Surgery       Date:  2000-03       Impact factor: 3.982

7.  Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial.

Authors:  Pierre J Guillou; Philip Quirke; Helen Thorpe; Joanne Walker; David G Jayne; Adrian M H Smith; Richard M Heath; Julia M Brown
Journal:  Lancet       Date:  2005 May 14-20       Impact factor: 79.321

8.  Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells.

Authors:  Lucy Golden-Mason; Brent E Palmer; Nasim Kassam; Lisa Townshend-Bulson; Stephen Livingston; Brian J McMahon; Nicole Castelblanco; Vijay Kuchroo; David R Gretch; Hugo R Rosen
Journal:  J Virol       Date:  2009-07-08       Impact factor: 5.103

9.  PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection.

Authors:  Constantinos Petrovas; Joseph P Casazza; Jason M Brenchley; David A Price; Emma Gostick; William C Adams; Melissa L Precopio; Timothy Schacker; Mario Roederer; Daniel C Douek; Richard A Koup
Journal:  J Exp Med       Date:  2006-09-05       Impact factor: 14.307

10.  Dysregulated T cell expression of TIM3 in multiple sclerosis.

Authors:  Ken Koguchi; David E Anderson; Li Yang; Kevin C O'Connor; Vijay K Kuchroo; David A Hafler
Journal:  J Exp Med       Date:  2006-06-05       Impact factor: 14.307

View more
  15 in total

1.  Rapamycin Prevents Surgery-Induced Immune Dysfunction in Patients with Bladder Cancer.

Authors:  Robert S Svatek; Niannian Ji; Essel de Leon; Neelam Z Mukherjee; Aashish Kabra; Vincent Hurez; Marlo Nicolas; Joel E Michalek; Martin Javors; Karen Wheeler; Z Dave Sharp; Carolina B Livi; Zhen-Ju Shu; David Henkes; Tyler J Curiel
Journal:  Cancer Immunol Res       Date:  2018-12-18       Impact factor: 11.151

2.  Functional impairment of infiltrating T cells in human colorectal cancer.

Authors:  Edward S Taylor; John L McCall; Adam Girardin; Fran M Munro; Michael A Black; Roslyn A Kemp
Journal:  Oncoimmunology       Date:  2016-09-26       Impact factor: 8.110

3.  Up-regulation of Tim-3 is associated with poor prognosis of patients with colon cancer.

Authors:  Encheng Zhou; Qing Huang; Ji Wang; Chengfeng Fang; Leilei Yang; Min Zhu; Jianhui Chen; Lihua Chen; Milian Dong
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

Review 4.  Tim-3 and Tim-4 as the potential targets for antitumor therapy.

Authors:  Lin Cheng; Zhihua Ruan
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer.

Authors:  Benling Xu; Long Yuan; Quanli Gao; Peng Yuan; Peng Zhao; Huijuan Yuan; Huijie Fan; Tiepeng Li; Peng Qin; Lu Han; Weijia Fang; Zhenhe Suo
Journal:  Oncotarget       Date:  2015-08-21

Review 6.  Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers.

Authors:  Vito Amodio; Gianluca Mauri; Nicole M Reilly; Andrea Sartore-Bianchi; Salvatore Siena; Alberto Bardelli; Giovanni Germano
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

7.  Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer.

Authors:  Chiao-Wen Kang; Avijit Dutta; Li-Yuan Chang; Jayashri Mahalingam; Yung-Chang Lin; Jy-Ming Chiang; Chen-Yu Hsu; Ching-Tai Huang; Wan-Ting Su; Yu-Yi Chu; Chun-Yen Lin
Journal:  Sci Rep       Date:  2015-10-23       Impact factor: 4.379

8.  PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients.

Authors:  X Wu; H Zhang; Q Xing; J Cui; J Li; Y Li; Y Tan; S Wang
Journal:  Br J Cancer       Date:  2014-08-05       Impact factor: 7.640

9.  Surgical Stress Abrogates Pre-Existing Protective T Cell Mediated Anti-Tumor Immunity Leading to Postoperative Cancer Recurrence.

Authors:  Abhirami A Ananth; Lee-Hwa Tai; Casey Lansdell; Almohanad A Alkayyal; Katherine E Baxter; Leonard Angka; Jiqing Zhang; Christiano Tanese de Souza; Kyle B Stephenson; Kelley Parato; Jonathan L Bramson; John C Bell; Brian D Lichty; Rebecca C Auer
Journal:  PLoS One       Date:  2016-05-19       Impact factor: 3.240

Review 10.  Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect.

Authors:  Julie Jacobs; Evelien Smits; Filip Lardon; Patrick Pauwels; Vanessa Deschoolmeester
Journal:  J Immunol Res       Date:  2015-10-29       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.